Earnings Call Summary | MediWound(MDWD.US) Q1 2024 Earnings Conference
Earnings Call Summary | MediWound(MDWD.US) Q1 2024 Earnings Conference
The following is a summary of the MediWound Ltd. (MDWD) Q1 2024 Earnings Call Transcript:
以下是MediWound Ltd.（MDWD）2024年第一季度業績電話會議記錄的摘要：
Financial Performance:
財務業績：
MediWound reported Q1 2024 revenue of $5 million, a significant increase compared to $3.8 million in Q1 2023, primarily due to revenue from Vericel and contracts with the U.S. Department of Defense.
The company recorded a net loss of $9.7 million or $1.05 per share in Q1 2024, a larger loss than the $3.7 million or $0.44 per share in Q1 2023.
As of the end of Q1 2024, MediWound had a total of $36 million in cash, cash equivalents, restricted cash, and deposits.
MediWound報告稱，2024年第一季度收入爲500萬美元，與2023年第一季度的380萬美元相比大幅增長，這主要歸因於來自Vericel的收入和與美國國防部的合同。
該公司在2024年第一季度錄得970萬美元的淨虧損，合每股虧損1.05美元，高於2023年第一季度的370萬美元，合每股虧損0.44美元。
截至2024年第一季度末，MediWound共有3,600萬美元的現金、現金等價物、限制性現金和存款。
Business Progress:
業務進展：
MediWound has secured a forecast for annual revenue orders totaling $24 million, with over 60 burn centers having applied.
Substantial progress has been recorded with NexoBrid, particularly in increasing patient numbers and orders from burn centers.
A new state-of-the-art manufacturing facility is scheduled for completion by mid-2024, with an expectation to be fully operational by 2025.
The FDA has accepted MediWound's supplemental BLA for NexoBrid's pediatric use, with a verdict expected later in the year.
The company plans to conduct the Phase III clinical trial for EscharEx in the second half of 2024, targeting to enroll 216 patients across 40 sites.
MediWound will be included in the Russell 3000 Index and the small-cap Russell 2000 Index as part of the 2024 Russell indexes reconstitution.
MediWound已經獲得了總額爲2400萬美元的年收入訂單的預測，已有60多個燒傷中心提出了申請。
NexoBRID已取得實質性進展，特別是在增加患者人數和燒傷中心訂單方面。
一座最先進的新制造工廠計劃於2024年中期完工，預計到2025年全面投入運營。
美國食品藥品管理局已接受MediWound的補充BLA供NexoBrid的兒科使用，預計將在今年晚些時候作出裁決。
該公司計劃在2024年下半年對eSchareX進行三期臨床試驗，目標是在40個地點招收216名患者。
作爲2024年羅素指數重組的一部分，MediWound將被納入羅素3000指數和小型股羅素2000指數。
More details: MediWound IR
更多詳情： MediWound 紅
Tips: For more comprehensive details, please refer to the IR website. The article is only for investors' reference without any guidance or recommendation suggestions.
提示：欲了解更多詳情，請訪問投資者關係網站。本文僅供投資者參考，不構成任何投資建議。
譯文內容由第三人軟體翻譯。